Microbix Biosystems (TSE:MBX) Posts Quarterly Earnings Results

Microbix Biosystems (TSE:MBX) posted its earnings results on Thursday. The company reported C($0.01) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of C$4.06 million for the quarter. Microbix Biosystems had a negative return on equity of 21.02% and a negative net margin of 38.62%.

Here are the key takeaways from Microbix Biosystems’ conference call:

• Positive Sentiment: Q3 revenue increased 17% year over year, with antigen sales up 20% and QAP sales up 13%. Management expects continued year-over-year and sequential growth in Q4, moving closer to break-even.
• Positive Sentiment: Gross margin improved to 54% from 41% a year earlier, aided by product mix, manufacturing efficiencies, higher yields, and better fixed-cost absorption.
• Positive Sentiment: Kinlytic development is progressing toward an FDA meeting on comparability protocols before year-end and an anticipated supplemental BLA filing in 2027. Process improvements have increased drug-substance yields and could improve future margins.
• Positive Sentiment: Microbix is pursuing several potentially material QAP projects with major international diagnostics companies, including synthetic controls for RNA-based viruses and products for assays on large installed instrument bases. Management expects initial customer-related disclosures during the balance of calendar 2026, although timing remains client-controlled.
• Negative Sentiment: The company remains a net user of cash and reported a quarterly net loss of approximately CAD 800,000, despite holding CAD 7.2 million in cash. Management is balancing share buybacks with preserving liquidity for potential production expansion and limiting the need for future equity financing.

Microbix Biosystems Stock Performance

TSE MBX traded down C$0.01 during trading hours on Friday, reaching C$0.29. 2,000 shares of the company were exchanged, compared to its average volume of 51,414. The stock has a market capitalization of C$40.56 million, a P/E ratio of -7.20 and a beta of 0.72. The business’s 50 day simple moving average is C$0.30 and its 200-day simple moving average is C$0.26. Microbix Biosystems has a 1 year low of C$0.21 and a 1 year high of C$0.32. The company has a quick ratio of 5.57, a current ratio of 5.35 and a debt-to-equity ratio of 27.03.

Insider Transactions at Microbix Biosystems

In other Microbix Biosystems news, Director Martin Marino purchased 115,000 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were bought at an average cost of C$0.28 per share, with a total value of C$32,200.00. Following the acquisition, the director owned 2,000,167 shares in the company, valued at approximately C$560,046.76. This trade represents a 6.10% increase in their ownership of the stock. Insiders have purchased 251,000 shares of company stock worth $68,355 in the last three months. Insiders own 14.00% of the company’s stock.

Microbix Biosystems Company Profile

Microbix Biosystems Inc creates proprietary biological products for human health, with over 120 skilled employees and revenues of C$ 18.6 million in its last reported fiscal year (2025). It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs ¿ ) and reference materials (QUANTDx ¿ ) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows.